Fibroblast growth factor 21 (FGF21) has been identified as a potential therapeutic target in the treatment of T2D and NASH. The effectiveness of mRNAs was evaluated by 2 weeks of repeated subcutaneous administration in mice. This shows significant reductions in body weight and plasma insulin levels as well as hepatic steatosis. The gene discussed is INS; the disease is Hepatic steatosis.